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Abstract 
Tacrolimus has been the drug of choice for prevention of graft rejection following organ 
transplantations. This systematic review and meta-analysis [UiTM1] was conducted to 
evaluate the efficacy of tacrolimus in organ transplantation. Publication in English of 
randomized clinical trials, which used tacrolimus to prevent graft rejection in adult patients 
were included in this analysis. Articles were searched from PubMed, Science Direct, 
Blackwell and Ovid Gateway, which were published since 1980 to 2007. The outcomes 
measured were biopsy-proven acute rejection at three months; graft survival at one year; 
post-transplant diabetes mellitus; hypertension and neurotoxicity. Seven reports, which 
involved 2415 participants showed that tacrolimus was associated with reduced odds of 
biopsy-proven acute rejections three months of post-transplantation (pooled odds ratio of 
0.69; 95% CI 0.49 to 0.96) and improved graft survival at one year (pooled odds ratio of 1.11 
and 95% confidence interval 0.72 to 1.71). In terms of adverse effects, tacrolimus-treated 
patients were significantly at high odds of developing post-transplant diabetes mellitus 
(pooled odds ratio of 1.90; 95% CI 1.09 to 3.30) and neurotoxicity (pooled odds ratio of 1.61; 
95% CI 1.15 to 2.25) but reduced odds of developing hypertension (pooled odds ratio of 0.80; 
95% CI 0.65 to 0.98). Low to moderate heterogeneity between trials existed for the 
incidences of biopsy-proven acute rejections, graft survival, post-transplant diabetes mellitus 
and incidence of hypertension; but the analysis showed a significant increment of 
neurotoxicity by tacrolimus. 
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